Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 139

A Phase 1/2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain tumor with no effective therapy and extremely poor prognosis (average 9 months of survival after diagnosis). Because of the location of DIPG tumors within the brainstem, surgical intervention is a highly invasive and imprecise option, as accidental removal of any ...

Precision Therapy to Overcome Chemoresistance in Pediatric Glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal forms of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor in glioblastoma, with a median overall survival of 14 months.1Currently, temozolomide (TMZ) is the preferred chemotherapeutic drug in the treatment of GBM ...

Modulation of intra-tumor hypoxia to sensitize DIPG irradiation and initiate ...

Malignant gliomas in specific region like brain pons are not curable as they cannot be surgically resected and are only transiently benefiting from local irradiation and in some cases from targeted therapies. These aggressive brain tumors are molecularly well known as they are characterized by a driver mutation. This abnormality ...

Targeting mitochondria-lysosome crosstalk as a therapeutic strategy for glioblastoma multiforme

Glioblastoma is the most common brain tumor. It is aggressive, and the therapeutic strategies focused on surgery, radiotherapy and chemotherapy are unable to destroy the tumor, which typically reappears post-treatment. The regrowth happens because the treatments are not able to destroy the cells that originate the tumor, called glioblastoma stem ...

Epigenetic Targeted Therapy and Resistance in AT/RT

Pediatric rhabdoid tumor in the brain, atypical teratoid/rhabdoid tumor (AT/RT), is a highly malignant brain tumor that has a very poor prognosis despite aggressive treatment. The development of new, effective therapeutic approaches for AT/RT has been hindered by a lack of specific therapeutic targets. It is necessary ...